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I-01
META-EPIDEMIOLOGY: BUILDING THE BRIDGE FROM RESEARCH
EVIDENCE TO CLINICAL PRACTICE
W. Zhang
Nottingham Univ., Nottingham, United Kingdom
Meta-epidemiology evolves from epidemiology and meta-analysis. It is a
subject which attempts to describe distribution of research evidence for
a speciﬁc question, examine heterogeneity and associated risk factors,
identify and control bias across studies and summarise research evidence
as appropriate. Unlike classic epidemiology, the observational subjects of
meta-epidemiology are papers not patients. It is therefore an observational
study in research evidence with a unique statistical method - meta-analysis.
The term “meta-epidemiology” ﬁrst appeared in literature in 1997 in David
Naylor’s editorial for meta-analysis in clinical research [1]. It was deﬁned
by Sterne and his colleagues in 2002 as a statistical method to identify
and quantify the inﬂuence of study level characteristics such as allocation
concealment in randomised controlled trials [2]. Since then, several papers
have been published with regard to “meta-epidemiology” [3,4]. The con-
cept, however, had not been generalised until 2007 when the Osteoarthritis
Research Society International (OARSI) had its ﬁrst systematic review of 51
treatments in osteoarthritis (OA) where research evidence including clinical
effectiveness and cost-effectiveness were analysed, compared and sum-
marised across treatments [5]. Meta-epidemiology is no longer a statistical
method, but instead translational research to close the gap between bench
work and bedside. The concept is further reinforced by the OARSI recent
update on research evidence in OA therapy [6]. A full picture of meta-
epidemiology starts fading into OA therapy with more epidemiological
aspects including distribution of evidence, change of evidence, associated
risk factors, bias of evidence, summary and clinical application of evidence.
Meta-epidemiology is not only a subject in the therapeutic area. It spreads
very quickly, for example into other OA areas, from genetic [7] to clinical
practice [8], from treatment effect [9] to contextual therapy [10], from
randomised control trials [11] to observational studies [12]. We anticipate
that in the next 5 years, this subject will further evolve to improve the
evidence based clinical practice.
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I-02
CARTILAGE INSIDE OUT
R. Poole
McGill Univ., Montreal, QC, Canada
Recent "inside" studies of the molecular pathology of cartilage degeneration
in osteoarthritis (OA) have provided a broad body of information. Much
of this can be explained by a unifying hypothesis involving chondrocyte
differentiation from what is normally seen in healthy uncalciﬁed articular
cartilage to a phenotype usually only found in endochondral ossiﬁca-
tion.This hypothesis and the mechanisms involved in regulation of this
chondrocyte hypertrophy will be reviewed.
New "outside" information involving the use of molecular biomarker anal-
yses of body ﬂuids to study joint pain will also be presented. This approach
shows promise in helping clarify our understanding of where joint pain
originates, especially in knee OA.
I-03
USINGMICROARRAYS TO INFORM LABORATORY AND CLINICAL PRACTICE
C.L. Murphy
Kennedy Inst. of Rheumatology, London, United Kingdom
Whether genome-wide, tissue, cell or pathway-speciﬁc, microarrays can be
a very useful tool in basic and translational science. With the development
of array technology, smaller and smaller amounts of RNA and therefore
tissue samples are required, and so the emphasis is on quality rather than
quantity of material used. However, meticulous experimental planning and
execution are crucial at every stage if meaningful data are to be obtained.
Firstly, careful consideration must be given as to whether arrays are the
right tool to answer the research question posed. For example, it must be
borne in mind that arrays yield gene expression data which are an average
of the sample being analysed. If that sample is complex, for example, a
tissue containing multiple cell types, then the results can be uninformative
if the goal is to understand a particular cell’s behaviour. In such cases, other
approaches may be more appropriate, for example, in situ hybridisation to
assess gene expression in a localised manner.
Another crucial aspect in array studies is the use of relevant controls
(positive or negative). Without such, no context can be provided for
interpretation of the data. This applies equally to all array-based studies.
One example is that of analysing gene expression of differentiating stem
cells. If experimentally induced differentiation to a particular cell type is
to be truly assessed, a comparison must be made with the terminally
differentiated cell in question. By way of illustration, if chondrogenic
differentiation of stem cells is being examined with regard to procuring
cells for articular cartilage repair therapies, then it is most important to
compare the stem-cell derived cells to mature articular chondrocytes. A
modest increase in chondrogenic markers in differentiating stem cells can
be shown to be less signiﬁcant if that gene expression remains orders of
magnitude less than that found in the mature chondrocyte.
If a disease such as osteoarthritis is being studied, controls, although hard
to obtain, remain essential. Comparing, for example, gene expression in
osteoarthritic cartilage to normal can be performed using tissue from the
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same subjects or different ones, with the advantage of potentially limiting
biological variability in the former case. Naturally, this is much easier to
achieve in animal studies rather than human, and problems are further
compounded by the fact of greater genetic variability in man compared to
inbred mouse strains. Unfortunately, to counter such limitations increased
sample numbers are often required to obtain signiﬁcant data from array
studies involving human tissue.
Microarrays are at their most powerful when used to address very well-
deﬁned research questions, for example, what is the effect of a speciﬁc
stimulus on a given cell type?; or, indeed in many plus/minus scenarios
(including knock-downs, knock-outs etc.). Another example along these
lines is the use of so-called RIP-Chip (immunoprecipiation of speciﬁc
proteins followed by array analysis) which is very useful when looking
at interactions between a single protein and many different RNA species.
In conclusion, array studies are most useful when applied to clearly de-
ﬁned research questions, and furthermore it is crucial to perform them
with utmost care both in experimental planning and execution to obtain
meaningful data. If such an approach is adopted array studies can be
extremely powerful as they can provide genuine new insights into many
pathophysiological processes.
I-04
INTRARATICULAR THERAPIES IN THE MEDICAL MANAGEMENT OF OA
T. Conrozier
CENTRE Hosp. Lyon-Sud, Pierre Bénite, France
Osteoarthritis (OA) is the most common joint disease, with millions of
affected individuals worldwide. The prevalence of the disease is increasing
with age and consequently the affected population is chieﬂy constituted of
frail and elderly people. Given the chronic and non-life-threatening nature
of OA, a good safety proﬁle of treatments is essential.
Intra articular (IA) therapy gives the opportunity to reduce the risks of
adverse events compared to systemic treatments such as non steroidal anti
inﬂammatory drugs and cox2-inhibitors, particularly in patients with co-
morbidities (renal failure, arterial hypertension, gastrointestinal diseases).
Furthermore the direct administration of the drug into the OA joint allows
to expose the cartilage and synovial tissues to higher concentrations of the
drug compared to those obtained via systemic route.
The main risk associated with intraarticular administration is septic arthri-
tis but this risk is very small, when proper sterile technique is used,
including sterile syringes and skin antisepsis (0.002% from the experience
of 50,000 IA injections of corticosteroids). Proper needle placement within
the intra-articular cavity deserves careful attention. Even experienced se-
nior physicians fail to place the needle within the joint cavity in 20 to
50% of cases according to the joint and the approach. For deep joints such
as the hip, or small joints such as the trapezo-metacarpial joint, imaging
guidance using ultrasonography or ﬂuoroscopy is crucial. To limit the risk of
inaccurate needle placement, aspiration of synovial ﬂuid is recommended.
Synovial ﬂuid aspiration is indispensable when there is a joint effusion and
may contribute to the treatment response either via a direct effect or by
diminishing the volume available for drug dilution.
To date, three types of IA therapies are routinely available for decreas-
ing pain and/or improving function in patients with OA: glucocorticoids,
hyaluronic acid, and joint lavage.
Steroids IA injections are recommended in patients with joint effusion and
in those with signs of inﬂammation. The short-term beneﬁt (<4 weeks)
of IA corticosteroids (CS) in the treatment of knee OA is well established
with a size effect on pain of 0.58 (95%CI 0.34-0.87), and few side effects
have been reported such as temporary disturbance of diabetes and arterial
hypertension.
The response to hyaluronic acid (HA) products appears similar (ES pain
0.60/CI 0.37-0.83) but much more durable than that of CS (up to 26
weeks). No major safety issues were reported apart from some transient
local adverse events such as pain, swelling. Recent studies also suggest
a possible structure-modifying effect of HA injections. The key question
with HA treatment is to precisely deﬁne the type of patients likely to be
responders to treatment.
Joint lavage and arthroscopic debridement are often proposed in patients
unresponsive to CS and/or HA treatments, but there is no evidence of their
eﬃcacy (ES pain 0.21/-0.12-0.54).
New perspectives of IA therapy in OA include anti-cytokine therapy, gene
therapy, delivery of growth factors, stem cells therapy and new lubricant
agents.
The main goal of IA therapy for OA in the future will be to increase the
residence time of the drug within the joint in order to improve its diffusion
within the target tissues. In all cases the treatment must be individualized
for each patient in order to adapt it to the speciﬁcs of his condition.
I-05
POST-TRAUMATIC OSTEOARTHRITIS REVISITED
S. Lohmander
Lund Univ., Lund, Sweden
OA is a multifactorial condition with genetic and environmental determi-
nants. All cases are inﬂuenced by both genetics and environment, with
the distribution and weight of causes forming a continuum between the
extremes of predominantly genetic or predominantly environmental. For
example, the risk of ‘post-traumatic OA’ after a meniscal injury of the knee
is inﬂuenced by a familial history of OA, by the presence of nodal OA of the
hand (marker of ‘generalized’ OA), by obesity, and by sex. The expression of
OA in any individual (presence or absence of inﬂammation, pain, cartilage
loss, bone formation, etc.) may further be determined by the particular mix
of genetic and environmental inﬂuences in that person.
OA where previous joint injury is identiﬁed as an important cause is
common, especially in younger persons. By 10-20 years after the rupture of
a cruciate ligament or meniscus of the knee, about half of those injured will
show radiographic signs of OA, and many will have signiﬁcant symptoms
already when aged 30 to 50. This represents an important clinical challenge
in that surgical resection or reconstruction of the torn meniscus or cruciate
ligament has not been proven to decrease the risk of OA development.
The young athlete with a knee injury leading to later OA may seem
straightforward to identify as post-traumatic OA, but the contribution
of additional risk factors as mentioned above should not be overlooked.
Moreover, the case deﬁnition is further muddled by the common presence
in middle-aged persons of incidental meniscus lesions associated with an
increased risk of knee OA development. Completing the continuum, lesions
of the menisci or cruciate ligament are frequent in OA knees, even in the
absence of a clear history of injury.
OA following joint injury offers unique opportunities for studying and
intervening in the earlier phases of human OA development. In parallel,
joint injury in the animal is a commonly used pre-clinical model for OA
development.
I-06
ENDOCHONDRAL OSSIFICATION SIGNAL: A POTENTIAL THERAPEUTIC
TARGET FOR OSTEOARTHRITIS
H. Kawaguchi
Univ. of Tokyo, Tokyo, Japan
Osteoarthritis (OA) is characterized by cartilage degeneration and osteo-
phyte formation in joints. Despite its high prevalence and social needs for
the disease-modifying treatment, the molecular backgrounds underlying
the OA development are not fully clariﬁed. Considering that most of risk
factors approved so far are related to accumulated mechanical stress on
joint, elucidation of signals lying downstream of the mechanical stress
will disclose the molecular backgrounds. Using mouse experimental OA
models by producing instability in the knee joints surgically, proteinases
like matrix metalloproteinase-13 (MMP)13 and aggrecanase-2 (ADAMTS-5)
have been reported to be involved in the OA development. However,
clinical trials of the proteinase inhibitors have to date been unsuccessful
in terms of eﬃcacy and side effects, turning the interest of researchers to
other signals.
Our examination using the experimental mouse model conﬁrmed that
MMP13 was induced during the OA progression in the knee joint cartilage,
but more interestingly, type X collagen (COL10A1) that is characteristic
of hypertrophic differentiation of chondrocytes was strongly expressed
prior to the MMP13 induction. Chondrocyte hypertrophy with COL10A1
expression is known to initiate the endochondral ossiﬁcation process which
is not seen in the joint cartilage under physiological conditions, but is an
essential step for skeletal growth and fracture healing. The hypertrophic
chondrocytes then degrade cartilage matrix by proteinases to cause vas-
cularization by expressing VEGF for the recruitment of osteoprogenitor
cells.
To identify signals to induce endochondral ossiﬁcation and OA develop-
